Factores de riesgo de la gastropatía por AINE

Revista Espanola de Reumatologia

Volumn 27, Issue 1, 2000, Pages 9-14

  Rodríguez Lozano, Carlos ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001146907     PISSN: 03044815     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Gabriel S, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use on nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-96.
2. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers: facts and figures multiply, but do they add up? BMJ 1990; 300: 278-84.
3. García Rodríguez L, Hershel J. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 243: 769-72.
4. Singh G. Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26 (Supl 56): 18-24.
5. Silverstein FE, Graham DY, Senior JR, Wyn Davies H, Struthers BJ, Bittman RM et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-49.
6. a ed.). Buenos Aires: Ed. Panamericana, 1994.
7. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995; 90: 206-10.
8. Griffin M, Joyce P, Daugherty MS, Snowden RN, Ray W. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63.
9. Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RFA et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8.
10. Henry D, Dobson A, Turner C. Variability in risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078-88.
11. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 213-22.
12. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104 (3A): S23-S29.
13. Henry D, Lim L, García Rodríguez LA, Pérez Gutthann S, Carson JL, Griffin M et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6.
14. Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976; 294: 473-9.
15. Messer J, Reitman D, Sacko HS, Smith H, Chalmers TC. Association of adrenocorticosteroid therapy and peptic ulcer disease. N Engl J Med 1983; 309: 21-4.
16. Piper JM, Ray W, Daugherty JR, Griffin M. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-40.
17. Carson JL, Strom BL, Schinnar R, Duff A, Sim E. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. The Am Journal Med 1991; 91: 223-8.
18. Shorr R, Ray W, Daugherty JR, Griffin M. Concurrent use on nosteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 1665-70.
19. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sáinz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroentrology 1997; 112: 683-9.
20. Lanas A, Sekar MC; Hirschowitz BI. Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103: 862-9.
21. Graham DY, White RH, Moreland LW, Schubert TT, Katz R, and the Misoprostol Study Group. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257-62.
22. Hawkey CJ, Karrasch J, Szczepanski L, Walker DG, Barkun A, Swannell AJ et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727-34.
23. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, Van Rensburg CJ et al, for the Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1988; 338: 719-26.
24. Bianchi Porro G, Parente F, Imbesi V, Montrone F, Carusso I. Role of Helicobacter pylori in culcer healing and recurrence of gastric and duodenalulcers in long-term NSAID users: response to omeprazole dual therapy. Gut 1996; 39: 22-6.
25. Chan FK, Sung JJ, Chung SC, Tok F, Yung MY, Leung VK et al. Randomised trial of erradication of Helicobacter pylori before non-steroidal anti-inflammatory drug theraphy to prevent peptic ulcers. Lancet 1997; 350: 975-9.
26. Hawkey CJ, Tulassay Z, Szczepanski L, Van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal antiinflammatory drugs: HELP NSAIDs Study. Lancet 1998; 352: 1016-21.
27. Singh G, Ramey DR, Morfelf D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid anthritis. A prospective observational cohort study. Arch Intern Med 1996; 156: 1530-6.
28. Singh G, Ramey DR, Triadafilopoulos G, Brown BW, Balise RR, GI SCORE: a simple self-assessment instrument to quantify the risk of serious NSAID-related GI complications in RA and OA. Arthritis Rheum 1998; (Supl): S75.
29. Furst DE. Meloxicam: selective COX-2 Inhibition in clinical practice. Seminars in Arthritis & Rheum 1997 (Supl): 21-27.
30. Dequeker J, Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E et al, on behalf of the SELECT Study Group. Improvement in gastrointestinal tolerabilily of the selective cyclooxigenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-51.
31. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14.